Two powerhouse medical groups are dragging a federal regulator into court, accusing the Federal Trade Commission of going way too far in its hunt for information about gender-affirming care for minors. The American Academy of Pediatrics and the Endocrine Society filed separate lawsuits Tuesday in federal court in Washington, D.C., asking judges to shut down what they describe as sweeping, unconstitutional record demands. The move ratchets up an already tense standoff between medical societies and federal agencies over how transgender youth care is guided, funded and policed.
What the complaints say
According to court filings, the AAP says the FTC hit the group on Jan. 15 with a civil investigative demand that seeks documents tied to the marketing and advertising of pediatric gender-dysphoria treatment. The Endocrine Society reports it received a similar demand on Jan. 20. As Reuters notes, both organizations argue that the document requests are politically driven and aimed at punishing groups that back treatment for transgender youth.
Each lawsuit asks the court to declare the FTC’s demands unlawful and to bar the agency from enforcing them while the litigation plays out. In other words, the groups want judges to slam the brakes on the inquiry before a single extra document has to be turned over.
FTC docket and petitions to quash
The fight is already bigger than these two lawsuits. Records posted in the Federal Trade Commission legal library show that the Endocrine Society, the World Professional Association for Transgender Health and other organizations have filed petitions to quash or limit similar civil investigative demands.
The FTC’s online docket lists administrative matter numbers and links to petition PDFs, signaling that multiple medical and professional groups are now targets of the agency’s information dragnet.
How the groups frame the agency action
In its complaint, the AAP accuses the FTC of using its enforcement tools to wage a policy fight it is losing in public debate. “Unable to prevail in the marketplace of ideas, the FTC has resorted to burdening AAP with an intrusive and expensive investigation that is unconstitutional and outside the scope of the FTC’s statutory authority,” the group wrote, according to Reuters.
The Endocrine Society makes similar claims in its filing, arguing that the agency’s demands sweep in communications, board materials and other records that do not resemble the kind of evidence typically sought in consumer-protection probes. Both plaintiffs say the requests are retaliatory, and warn that complying would be enormously costly for organizations that help set national standards for pediatric and endocrine care.
Where this fits in the wider policy fight
The lawsuits land against a backdrop of broader federal efforts to reshape how agencies treat programs involving transgender people. Last year’s executive actions directed agencies to curb federal backing for initiatives the administration labels as promoting “gender ideology.” Lawyers for the medical groups point specifically to a Jan. 20, 2025 White House executive order as part of that regulatory push.
Courts have already stepped in on related issues this year. Litigation trackers highlight a January ruling that temporarily blocked the Department of Health and Human Services from cutting roughly 12 million dollars in grants to the AAP, and the new suits add another test of how far federal agencies can go when they scrutinize medical guidance and speech. Public documents from the White House and case summaries maintained by Just Security map out those related challenges.
What comes next in court
Both the AAP and the Endocrine Society are asking for fast judicial intervention. The AAP wants an order blocking enforcement of the FTC’s document demand, while other groups are pressing judges to quash or at least narrow the subpoena-style requests.
The FTC’s own legal library and federal court dockets already list multiple related petitions and complaints. Judges are expected to tackle threshold fights over how broad and how fast the agency’s demands can be enforced before anyone gets to the deeper questions about the FTC’s authority. If courts trim back the requests, the ruling could curb how aggressively the FTC can wield civil investigative demands in contentious health policy disputes. If the agency prevails, it could gain a far wider window into the internal workings of professional medical societies.
For now, the cases put a powerful regulator, influential medical organizations and federal judges squarely in the middle of the national showdown over transgender health care and government reach. Courts in Washington will begin setting briefing and hearing schedules in the coming weeks, and those decisions will help determine whether this becomes a new normal in federal enforcement or a short-lived test that gets cut off by the judiciary.
